Welcome on the Necker-Enfants Malades Institute website
  • Découverte d’un nouveau marqueur de risque cardiovasculaire chez les patients DT2 - Nos chercheurs à l’honneur
    Un nouveau marqueur pronostic de risque cardiovasculaire chez les personnes atteintes de diabète de type 2 (DT2) a été identifié par l’équipe IMMEDIAB – Immunité et [...]
  • New Marker for Cardiovascular Risk in Type 2 Diabetes Patients – Our researchers in the spotlight
    A novel prognostic marker for cardiovascular risk in individuals with type 2 diabetes (T2D) has been identified by the IMMEDIAB team – Immunity and Metabolism in Diabetes, led by Nicolas Venteclef at [...]
  • Unlocking the Mysteries of Brain Function - New Publication in Cell Death & Disease by Integrative Neurobiology team

    Slc20a1 and Slc20a2 regulate neuronal plasticity and cognition independently of their phosphate transport ability

    In recent years, significant strides have been made in understanding rare neurological diseases like Primary Familial Brain Calcification (PFBC) an inherited form of neurological [...]
  • Hommage au Professeur Jean-François Bach

    C'est avec une profonde tristesse que nous vous faisons part du décès du Professeur Jean-François Bach, survenu le 12 décembre 2023 à l'âge de 83 ans. Le Professeur Bach a consacré l'intégralité de sa carrière en tant que médecin et scientifique à l'hôpital Necker, [...]

  • Just published: Airway environment drives the selection of quorum sensing mutants and promote Staphylococcus aureus chronic lifestyle
    In their recently published study, Xiongqi Ding et al. (Team Pathogenesis of systemic infections) shed light on a critical aspect of chronic lung diseases : how the airway environment influences the behavior of S. aureus, a key player in these infections, particularly cystic fibrosis [...]
  • Just Published: The AMPK-Sirtuin 1-YAP axis is regulated by fluid flow intensity and controls autophagy flux in kidney epithelial cells by Aurore Claude-Taupin
    In their recently published paper in Nature Communications, Aurore Claude-Taupin et al. explore the critical role of shear stress, a known regulator of renal function, and its dysregulation in various kidney diseases.
    Building on prior research highlighting the significance [...]
The Institute
The Institut Necker-Enfants Malades (INEM), created in January 2014, is an international biomedical research center located on the Necker Hospital campus, and supported by the French National Institute of Health and Medical Research (INSERM), the French National Center for Scientific Research (CNRS) and the University of Paris.

Research at INEM is focusing on common diseases caused by the interplay of polygenic inheritance and environmental factors. These diseases primarily affect children and the young, and encompass (auto)immune disorders, haematological diseases, infectious diseases, kidney diseases, cystic fibrosis, endocrinological disorders and metabolic diseases. The INEM teams apply insights obtained through basic and clinical research to develop innovative diagnostic and therapeutic strategies.

For over 40 years, the development of renal transplants and bone marrow transplants, the phenotyping of autoimmune diseases and genetic diseases, allowed most of the major medical advances of today. The major asset of the Institute Necker-Enfants Malades comes from the plurality of skills, the freedom and creativity of its researchers, their desire to diversify their research topics.

Translational activities will be pursued and promoted as much as possible. Indeed, this group of PIs has filed 24 patents, 4 of which are licenced to pharmaceutical companies. 13 R&D contracts have been signed with industry and 3 start-up companies incorporated with one of the above PIs as founder. To further strengthen the link with the socio-economic world, we intend to devote one floor of our research building to hosting private entities, either small companies or teams from bigger pharmaceutical industries wishing to collaborate with groups of the Necker-Enfants Malades Institute.

Our mission

The close interaction between the research labs and the clinical departments is one of our major strengths creating a highly dynamic environment and promoting translational and “bench to bedside” activities. Our research programs are consistent with this mission and most groups have very tight connections with the clinics, mostly through clinicians with joint appointments in research labs and clinical departments.

Our research in the coming years will focus on:
  • Understanding the molecular mechanisms of leukemia is to use targeted therapies and avoid chemotherapy whose collateral damage is known
  • Defeating diabetes, especially the type 1 in children (440,000 in the world), is to address the treatment of autoimmune diseases, more and more frequent in developed countries, as the case for multiple sclerosis or lupus.
  • Succeed one day to control the immune system, thanks to the long experience and considerable clinical material at the Necker hospital on kidney and bone marrow transplantations, is a priority
  • Seek to determine the mechanisms responsible for bacterial meningitis, debilitating in a few hours a perfectly healthy child or subject, is essential to develop effective and safe vaccines.
  • Apply our knowledge of metabolism and growth to promote innovative and personalized therapies in the field of kidney disease, diabetes, cystic fibrosis, muscular dystrophy and various solid tumors.
The Necker-Enfants Malades Institute is administered by one Director assisted by the two department Heads and one General secretary in charge the administration. Each PI or CoPI is responsible for his (her) scientific project and for the use of his (her) allocated space
Fabiola Terzi
INEM Director
Mario Pende
Marco Pontoglio
Director of "Growth and Signalling" Dept
Peter Van Endert
Simon Fillatreau
Director of "Immunology, Infectiology and Haematology" (I2H) Dept
Sabine Barbut
General Secretary
The scientific teams
The people of INEM

Thirteen research teams are founding members of the Necker-Enfants Malades Institute, which comprises today 20 research teams. The teams are grouped in two departments: a department of Cell biology (Growth and Signalling) and a department of, Immunology, Infectiology and Haematology (I2H).

The Necker-Enfants Malades Institute currently comprises 103 senior scientists, one third of whom are medical doctors, 60 technicians and engineers, 35 postdoctoral fellows and 37 PhD students. Among the 19 teams, 7 have already obtained an award from the European Research Council.

Scientific Advisory Board
The Scientific Advisory Board (SAB) is composed of 8 international scientific personalities, experts in their field. Its role will be to advise the INEM on scientific orientations and the recruitment of new groups. If necessary, the SAB might be consulted for strategic decisions. 
Anna Katharina (Katja) Simon
Cédric Blanpain
Sarah-Maria Fendt
Stefan H.E. Kaufmann
Stephen Lory
Helen McNeill
Marco Sandri
Kenneth Smith
Contact us
Institut Necker Enfants Malades

Faculté de Médecine Necker
160, rue de Vaugirard
75015 Paris Cedex
HRH Princess Caroline of Hanover, who through the Princess Grace Foundation, already supports medical research and anything that helps to relieve the sick children in France and around the world, has agreed to commit to our side so that our Center of Molecular medicine continues to meet the current challenges and fight diseases, and in particular the ones affecting children.

INEM - Organigramme